Aurobindo Pharma reported strong growth for Q2 FY27, with revenue rising 24% to Rs 10,263 crore and net profit climbing 33% to Rs 1,126 crore. Growth was powered by robust US and European demand, alongside the successful integration of the Lannett acquisition. The company remains in a healthy net cash position of US$ 189 million, signaling stable operations as it scales its biosimilar manufacturing capabilities.
Aurobindo Pharma Q2 Profit Rises 33% to Rs 1,126 Crore
Revenue grew 24% YoY to Rs 10,263 crore; EBITDA margins expanded by 75 bps to 21%.
Reader Takeaway: Strong US volume gains and the Lannett acquisition drive results, though biosimilar regulatory timelines remain crucial.
What just happened
Aurobindo Pharma has posted a strong set of results for the quarter ended September 30, 2026. The company reported a net profit of Rs 1,126 crore, a significant increase from Rs 848 crore in the same period last year. Revenue saw a healthy 24% climb, reaching Rs 10,263 crore, supported by double-digit growth across its key geographies.
Why this matters
The performance highlights the firm's successful execution in the US and European markets. Notably, the US business grew by 25.2%, bolstered by 10 new product launches, including the gAdvair generic and its first New Chemical Entity (NCE), ADQUEY. The successful integration of the Lannett acquisition has provided a clear inorganic boost, enhancing the company’s portfolio in complex and controlled substances.
Strategic focus and Capex
The company is aggressively investing in its future pipeline, with net Capex of US$ 89 million for the quarter. A major highlight is the ongoing construction of a 10,000L mammalian cell-culture bioreactor, aimed at scaling its biosimilars business. With products like Omalizumab and Denosumab in the regulatory and clinical pipeline, the company is positioning itself for high-value segment growth.
Balance Sheet strength
Financial stability remains a key theme, with the company ending the quarter in a net cash position of US$ 189 million. Despite strategic spending and dividend payouts, it maintained positive net cash flow of US$ 146 million, providing a buffer for future expansion.
What to track next
Investors should monitor the regulatory progress of ongoing biosimilar filings and the pace of commercialization for new launches in the US. Additionally, the company's ability to maintain margin profile while integrating manufacturing assets will be a key focus area for analysts in the coming quarters.